ArticleLaboratory investigation; a journal of technical methods and pathology2018

Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma.

Wen-Juan Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.